Sep 18, 2020 / 04:35PM GMT
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity Research
Good afternoon and good evening, everybody. Thanks for joining us for our final company presenter at the BofA Global Healthcare Conference. My name is Jason Gerberry, smid-cap biotech analyst at BofA. And I'm pleased to be introducing Ionis and Brett Monia, CEO of Ionis.
And Ionis, for those of you on the line who don't know, is a leader in antisense oligonucleotide therapeutics, or ASOs as we may refer to them on the call. So first off, Brett, thanks for joining us.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Thank you, Jason. It's a pleasure to be here.
Questions and Answers:
Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity ResearchYes. So hopefully next year, we'll actually be in London, but maybe we can just start big picture. And I think it's timely, given you'll have updates in the fourth quarter around new dosage form, or say new routes of
Trustpilot
